Deal facts
- Buyer
- Nuformix plc
- Target
- Biovara Limited
- Deal value
- Not disclosed
- Announced
- 11 November 2026
- Status
- Possible offer
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- shares
Sources
Nuformix plc (LSE: NFX) announced on 11 November 2026 that it has signed heads of terms with Biovara Limited, a privately owned UK pharmaceutical development company, for a proposed acquisition of Biovara's entire issued and to be issued share capital through a share-for-share exchange. The heads of terms are principally non-binding, other than certain provisions on confidentiality, exclusivity, costs, termination and other customary matters, and Nuformix says there is no certainty the deal will proceed or as to its final terms.
The company describes the combination as a merger of equals. Nuformix would issue new ordinary shares as consideration, and the combined valuation of the enlarged group is still to be agreed, so no deal value has been disclosed. Biovara's lead asset, LipAprep, is a lipid-based formulation of aprepitant for lung cancer-related cough that has completed a single ascending dose Phase 1 study. It would sit alongside Nuformix's NXP002, an inhaled formulation of tranilast for idiopathic pulmonary fibrosis and other fibrotic interstitial lung diseases, which has US and European Orphan Drug Designation. Nuformix says its existing discussions with potential licensing partners for NXP002 continue in parallel.
The structure carries listing consequences. Nuformix intends to seek cancellation of its listing on the Equity Shares (Transition) category of the Official List and of its trading on the London Stock Exchange Main Market, with the enlarged group's shares admitted to AIM. The acquisition may constitute a reverse takeover under the UK Listing Rules. If so, Nuformix would not be eligible for re-admission to the equity shares (transition) category on completion, and if AIM admission did not proceed it would need an FCA-approved prospectus to remain listed on the Main Market. SP Angel Corporate Finance LLP has been appointed as Nuformix's financial adviser and is intended to act as nominated adviser and joint broker to the enlarged group after admission, subject to due diligence and regulatory requirements.
The terms remain subject to satisfactory reciprocal due diligence, further negotiation, definitive transaction documentation, and all necessary regulatory and shareholder approvals. Nuformix shareholders would need to approve certain resolutions at a general meeting, including authorities to issue new shares. The transaction is also likely to need a Takeover Panel waiver of the Rule 9 mandatory offer obligation, subject to approval by independent Nuformix shareholders. Completion would also depend on the Main Market cancellation, publication of an AIM admission document and AIM admission. The heads of terms provide for a six-month exclusivity period and a long-stop date of 30 April 2027.
Deal timeline
1 update- Possible offer
Proposed Acquisition of Biovara
Disclaimer* THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) No. 596/2014 WHICH IS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND ("UK") PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS ( SI 2019/310 ) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK
LSE RNS
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Indivior Pharmaceuticals, Inc. to acquire Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. agreed to combine in an all-stock merger of equals. The merger agreement was signed on August 1, 2026,…
- Buyer
- Indivior Pharmaceuticals, Inc.
- Target
- Supernus Pharmaceuticals, Inc.
- Deal value
- Not disclosed
- Deal type
- merger of equals
Fortitude Mining Holdings, Inc. to acquire HeartSciences Inc.
Fortitude Mining Holdings, Inc. and HeartSciences Inc. have agreed to merge in a transaction structured as a merger of equals. Both companies are based in the United Sta…
- Buyer
- Fortitude Mining Holdings, Inc.
- Target
- HeartSciences Inc.
- Deal value
- Not disclosed
- Deal type
- merger of equals
Apimeds Pharmaceuticals US, Inc. to acquire MindWave
Apimeds Pharmaceuticals US, Inc. and MindWave entered the Exit Mode archive.
- Buyer
- Apimeds Pharmaceuticals US, Inc.
- Target
- MindWave
- Deal value
- Not disclosed
- Deal type
- merger of equals
QT Imaging Holdings, Inc. to acquire QT Imaging, Inc.
QT Imaging Holdings, Inc. and QT Imaging, Inc. have agreed to merge in a transaction valued at undisclosed terms. The deal structure involves consideration through share…
- Buyer
- QT Imaging Holdings, Inc.
- Target
- QT Imaging, Inc.
- Deal value
- Not disclosed
- Deal type
- merger of equals
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Buyer history
Nuformix plc
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive